Mwanzo500124 • BOM
Dr Reddy's Laboratories Ltd
₹ 1,192.80
28 Nov, 13:42:53 GMT +5:30 · INR · BOM · Kanusho
HisaHisa zinazouzwa INMakao yake makuu ni IN
Bei iliyotangulia
₹ 1,200.50
Bei za siku
₹ 1,188.65 - ₹ 1,210.40
Bei za mwaka
₹ 1,074.35 - ₹ 1,420.20
Thamani ya kampuni katika soko
993.98B INR
Wastani wa hisa zilizouzwa
elfu 58.81
Uwiano wa bei na mapato
18.63
Mgao wa faida
0.67%
Ubadilishanaji wa msingi
NSE
Alama ya CDP ya Tabia Nchi
A-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(INR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
80.16B16.51%
Matumizi ya uendeshaji wa biashara
29.72B24.54%
Mapato halisi
12.55B-15.18%
Kiwango cha faida halisi
15.66-27.20%
Mapato kwa kila hisa
15.83-11.13%
EBITDA
22.02B8.53%
Asilimia ya kodi ya mapato
30.01%
Jumla ya mali
Jumla ya dhima
(INR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
63.07B-7.15%
Jumla ya mali
465.96B34.27%
Jumla ya dhima
156.67B66.79%
Jumla ya hisa
309.28B
hisa zilizosalia
833.05M
Uwiano wa bei na thamani
3.28
Faida inayotokana na mali
10.24%
Faida inayotokana mtaji
13.21%
Mabadiliko halisi ya pesa taslimu
(INR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
12.55B-15.18%
Pesa kutokana na shughuli
9.32B-48.03%
Pesa kutokana na uwekezaji
-19.07B-322.21%
Pesa kutokana na ufadhili
16.15B329.53%
Mabadiliko halisi ya pesa taslimu
6.37B1.03%
Mtiririko huru wa pesa
3.92B-72.47%
Kuhusu
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1984
Wafanyakazi
27,048
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu